The Code of Ethics and Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature.
The application of the following principles is guaranteed by the existence of procedures within the Group aimed at ensuring that its employees, internal bodies and third parties acting on its behalf, operate effectively in accordance with ethical principles.
This version of the Code has been approved by the Board of Directors of Chiesi Farmaceutici S.p.A., in 2021. This constitutes an official Group document and as such is binding upon all the bodies, employees, consultants, collaborators, agents and, at a more general level all third parties acting on behalf of the Group.
In order to uphold the high legal and moral standards of the Group, Chiesi also adopted an Anti-Bribery Policy in 2015. The purpose of this policy is to provide anyone acting on behalf of or in the interests of Chiesi with a series of general principles on how to recognise and deal with situations involving corruption and how to comply with related regulations.
DISCLOSURE
EFPIA
As a member of EFPIA (European Federation of Pharmaceutical Industries and Associations) and ARPharM (The Association of the Research-based Pharmaceutical Manufacturer in Bulgaria) we are fostering the transparency on the interaction between the pharmaceutical industry and health care professionals & organisations according EFPIA, as well as all national legal regulations, as we are convinced to be independent partners with the same goal: cooperation and exchange of knowledge, as well as research and development without tortious interference or influence.
Disclosure DATA:
INDIVIDUAL DISCLOSURE
Donations and grants to HCO, HCP’s organisations and associations, organisations providing healthcare;
Costs related to Events: registration fees, sponsorship agreements, travel and accommodation;
Fees for Service and Consultancy to HCPs and HCOs: fees and related expenses must be disclosed separately. This is only applicable, when the HCPs or HCOs have provided their consent on the individual disclosure, otherwise the data needs to be published in the aggregated disclosure data
AGGREGATE DISCLOSURE
R&D costs: including costs for related events (investigators’ meetings, etc);
Transfers of value which cannot be disclosed on an individual basis for legal reasons
Disclosure DATA – 1st of January 2021 – 31 December 2021 , Methodolgy 2021
Disclosure DATA – 1st of January 2022 – 31 December 2022, Methodolоgy 2022
Disclosure DATA – 1st of January 2023 – 31 December 2023, Methodology 2023
Disclaimer: Publication of transfers of value to Recipients aims at reporting the values (monetary or in-kind) to HCPs/HCOs our company is collaborating / has relationships with, following the objectives and provisions included in the applicable codes. Individual disclosures have been consented to by individual Recipients – such consent has been given to allow complying with the applicable codes that our company signed off to. These publications do not grant a general permission for those accessing our website or the national platforms to undertake additional processing of the healthcare professionals’ data.
For a good understanding of the reporting included in our disclosures as published on this website, we refer to the Methodological Note that clarifies the meaning and content of the transfers of value reported.
For more questions on the EFPIA code or concerning a disclaimer or revocation of your consent to the individual disclosure, do not hesitate to contact us on the EFPIA code or concerning a disclaimer or revocation of your consent to the individual disclosure, do not hesitate to contact us.
List of Patient Organizations supported by Chiesi Bulgaria
in 2021:
Foundation “National Fund St. Nicola”
Partial support for the purchase of a pressure chamber for the needs of the Center for Children and Youth with Disabilities "Zornitsa", Vratsa for treatment with soft hyperbaric oxygen therapy for children with disabilities - BGN 4000
Foundation “Our Premature Babies”
Financial support of the project - National program for premature children, implemented by the Center for Child Development "Little Miracles" - BGN 10000
Association "Organization of Thalassemic patients in Bulgaria"
Partial financial support for the initiatives of the OTB Association - holding a general election meeting, medical consultations, research, purchase of disinfectants for patients in difficulty, administrative, legal and accounting costs of the association – BGN 7000.
“Cystic Fibrosis Association”
Financial support for the purchase of medical devices – nebulizers for the use of medicinal products for therapy in patients with cystic fibrosis – BGN 10000.
2022:
Foundation “Our Premature Babies”
Financial support for the implementation of an information campaign in connection with the World Day of Premature Children - November 17. The information campaign concerns the problems of these children and their families, the need for timely and long-term follow-up of premature children in Bulgaria- BGN 10 000.
“Cystic Fibrosis Association”
Financial support for the purchase of medical devices – nebulizers for the use of medicinal products for therapy in patients with cystic fibrosis – BGN 20 000.
2023:
Foundation “Our Premature Babies”
Financial support for the implementation of an information campaign in connection with the World Day of Premature Children - November 17. Partial financial support for an information campaign related to the problems of premature children – 11 000 BGN
Association "Organization of thalassemic patients in Bulgaria"
Support of an in vitro program related to research and preparation of patient-parents for assisted reproduction. Partial sponsorship of regional meetings planned by the Association 4 900 BGN.
Association "Bulgarian Alliance for Blood Donation"
Partial financial support for expenses related to organized blood donation campaigns -1 470 BGN.
Foundation “Benign Hematology”
Partial financial support for the implementation of a screening program for patients with beta-thalassemia – 4 000 BGN.
